Colforsin (Forskolin)

For research use only. Not for use in humans.

製品コードS2449 別名:Coleonol, Colforsin

Colforsin (Forskolin)化学構造

CAS No. 66575-29-9

Colforsin (Forskolin, Coleonol, Colforsin) is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology. Forskolin also activates PXR and FXR activity. Forskolin stimulates autophagy.

サイズ 価格(税別)  
JPY 20200
JPY 46800
JPY 63400
JPY 96600
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(78)

製品安全説明書

cAMP阻害剤の選択性比較

生物活性

製品説明 Colforsin (Forskolin, Coleonol, Colforsin) is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology. Forskolin also activates PXR and FXR activity. Forskolin stimulates autophagy.
ターゲット
Adenylyl cyclase (AC) [1]
(A wide variety of cell types)
体外試験

Forskolin increases cAMP levels in preparations of membranes, cells, or tissues. Forskolin not only activates AC but also interacts with certain other proteins, including glucose transporters and ion channels. Forskolin is able to promote activation of nine different transmembrane iso-forms of AC, albeit with somewhat less efficacy for AC9, which could be used to provides a means to identify and quantify high-affinity binding sites, i.e., G-proteins (Gs)–AC complexes. Activation of s by GPCRs contributes to Forskolin-stimulated cAMP generation in cells because of s-Forskolin potentiation of AC activity. [1] Forskolin stimulates adenylate cyclase activity without interacting with cell surface receptors. Forskolin's potentiation of cAMP in turn inhibits basophil and mast cell degranulation and histamine release, lowers blood pressure and intraocular pressure, inhibits platelet aggregation, promotes vasodilation, bronchodilation, and thyroid hormone secretion, and stimulates lipolysis in fat cells. Forskolin inhibits the binding of platelet-activating factor (PAF), independently of cAMP formation, which may be a result of Forskolin's direct effect on PAF or via interference with PAF binding to receptor sites. Forskolin also appears to have an effect on several membrane transport proteins, and inhibits glucose transport in erythrocytes, adipocytes, platelets, and other cells. Forskolin is used to treat with glaucoma. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29  MYTBdI9xfG:|aYOgRZN{[Xl? NULlbIhJPDEEoN88US=> M{iyTFQ5yqCq M{\RcWROW09? MYXpcoR2[2W|IHPoZY5o\XNiaX6geIhmKHCqb4PwbI9zgWyjdHnvckB{fGG2dYOgc4YhWFB{QTD0ZZJo\XS| Mn:zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
SW480 MXzBdI9xfG:|aYOgRZN{[Xl? NEjjOnc1OMLizszN Ml\2OFjDqGh? M{TsWGROW09? MXXpcoR2[2W|IHPoZY5o\XNiaX6geIhmKHCqb4PwbI9zgWyjdHnvckB{fGG2dYOgc4YhWFB{QTD0ZZJo\XS| NYK1RVUxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5PVc1PTFpPkK0PVk4PDVzPD;hQi=>
HT-29  M{PFXmFxd3C2b4Ppd{BCe3OjeR?= NH\6[4U1OMLizszN Mn7zOFjDqGh? MWrEUXNQ NY[0OVlycW6mdXPld{BidiCjY4TpeoF1cW:wIH;mJINie3Cjc3WgN{84 MlHsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
SW480 MULBdI9xfG:|aYOgRZN{[Xl? MWq0NOKh|ryP NIHsV3Y1QMLiaB?= Mmn0SG1UVw>? Mn\MbY5lfWOnczDhckBi[3SrdnH0bY9vKG:oIHPhd5Bie2ViMz:3 NYHONopSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5PVc1PTFpPkK0PVk4PDVzPD;hQi=>
HT-29  NWf5UIhXTnWwY4Tpc44hSXO|YYm= MnL5OFDDqM7:TR?= MkTkO{Bl MWPEUXNQ MWTy[YR2[2W|IHPvcI9vd3OyaHXy[UBnd3KvYYTpc44h[2GyYXLpcIl1gcLi MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl7N{S1NUc,OjR7OUe0OVE9N2F-
SW480 M1XWfGZ2dmO2aX;uJGF{e2G7 NVnKVVBpPDEEoN88US=> MXu3JIQ> NXSyR5IxTE2VTx?= MXPy[YR2[2W|IHPvcI9vd3OyaHXy[UBnd3KvYYTpc44h[2GyYXLpcIl1gcLi NHvTbW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5O|Q2OSd-MkS5PVc1PTF:L3G+
HT-29  Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojkOFDDqM7:TR?= MUOwMVczKGh? M3XFR2ROW09? NWXSbFBvcW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? NUPnNVNNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5PVc1PTFpPkK0PVk4PDVzPD;hQi=>
SW480 MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LPZVQxyqEQvF2= MVWwMVczKGh? M1jV[2ROW09? M4XJeYlvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWg[IVx\W6mZX70cJk> NVG4cGdoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5PVc1PTFpPkK0PVk4PDVzPD;hQi=>
HT-29  NIDVVnFHfW6ldHnvckBCe3OjeR?= NEPvdGw1OMLizszN NFnRcpc1QMLiaB?= NHSzNolFVVOR NYG0dllU[WO2aY\heIV{KFCSMlG= MoDrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
SW480 M{PGVWZ2dmO2aX;uJGF{e2G7 Mm\5OFDDqM7:TR?= MlTqOFjDqGh? MXjEUXNQ MnT2ZYN1cX[jdHXzJHBROkF? M3PLVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUm3OFUyLz5{NEm5O|Q2OTxxYU6=
C6 MYnGeY5kfGmxbjDBd5NigQ>? NI[2Z3gyOCEQvF5CpC=> NHXDTo8zOCCvaX6= M4rZXIlv[3KnYYPld{BkSU2SIHHjZ5VufWyjdHnvci=> MnX3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNkm0NVcoRjJ3ME[5OFE4RC:jPh?=
Huh-7 M{LHTWZ2dmO2aX;uJGF{e2G7 M{H0T|AuOjBizszN MXyyJIjDqA>? NGX5bHFz\XO3bITzJIlvKGFiZH;z[U1l\XCnbnTlcpQhcW6lcnXhd4UhcW5iYz3NfYMh\XiycnXzd4lwdiCjdDD0bIUheHKxdHXpckBidmRibWLORUBt\X[nbIO= NHn5eWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGwPVg{PCd-MkWxNFk5OzR:L3G+
THP-1  MmfySpVv[3Srb36gRZN{[Xl? M{K5VVEwOTBizszN M1LwNVLDqGh? M3;VbGROW00EoB?= MWHzeZBxemW|c3XzJG1EWC1zIIDyc4R2[3Srb39CpC=> MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF3NEi4Nkc,OjVzNUS4PFI9N2F-
BeWo  NFLzO3pHfW6ldHnvckBCe3OjeR?= MVOyNEDDvU1? NIH1WW81QCCq Mm\oSG1UV8Li M1XaT4lv\HWlZYOgZ4VtdCCodYPpc44> NWXlV4NORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxPFQ1PzdpPkK1NVg1PDd5PD;hQi=>
ventricular cardiomyocytes  NHHxbFBHfW6ldHnvckBCe3OjeR?= NXK5OJRFOC5yMT2xNEDPxE1? M1X1doV3d2unczDhckBqdm:2cn;wbYMhemW|cH;ud4UhOTJywsGxOUUh[WKxdnWgZoF{[Wxid3n0bEBidiCHQ{WwxsBw\iB{LkKgxtVO MmXoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MEOxNVMoRjJ3MkCzNVE{RC:jPh?=
ventricular cardiomyocytes  NXyyZlc4TnWwY4Tpc44hSXO|YYm= M1;X[VAvODFvMUCg{txO M{ThV4lv[3KnYYPld{Ah[0GPUDDhZ4N2dXWuYYTpc44> NYrYWYFoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNFMyOTNpPkK1NlA{OTF|PD;hQi=>
MIN6  NXfSRmtvTnWwY4Tpc44hSXO|YYm= MojHNVAh|ryPwrC= NUnTWnpLOyCq MnLrbY5kemWjc3XzJGQ{KG2UTlGg[ZhxemW|c3nvci=> M3z6RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkSxNVI1Lz5{NUK0NVEzPDxxYU6=
L6 NE\Ee2dHfW6ldHnvckBCe3OjeR?= MkDKOFAhyrWP NFTG[|AzPCCq MkfubY5pcWKrdIOgSG1JOS2rbnT1Z4VlKEGtdDDhZ5RqfmG2aX;u NUjnbmtVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOFc2PTBpPkK1NlQ4PTVyPD;hQi=>
HEK‐CFTR MnLlSpVv[3Srb36gRZN{[Xl? MUey5qCUPTEEoN88US=> NHfESHcxNTF{IH3pci=> Mny4SG1UV8Li MV7pcoR2[2W|IHGg[I9{\eLCkHTldIVv\GWwdDDpc4Rq\GViZX\mcJV5yqB? NGfkSFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2N|IxPyd-MkWyOlMzODd:L3G+
SK-N-SH NI[1PZFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NH;KRW4yOCEQvF5CpC=> M3vMNlQ5KGh? MoS0[Y5p[W6lZYOgV2suVi2VSDDu[ZVzd2KuYYP0c41iKGOnbHygeoli[mmuaYT5 NIHseGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2OlA3Oyd-MkWyOlYxPjN:L3G+
SK-N-AS  M3\xN2Z2dmO2aX;uJGF{e2G7 NX\FSFUzOTBizszNxsA> NHq3SooyOC9|MD:2NEBucW5? NGfsWmVqdmO{ZXHz[ZMhdGW4ZXzzJI9nKHBvzsKtZ4F1\W6rbjCod4VzPjd3KTDhcoQhcW6mdXPld{Bi[2O3bYXsZZRqd25ib3[gdE3Pui2lYYTlcolvKCi|ZYK2O|UqKGmwIDjw[ZJqMW63Y3zlZZIhemWpaX;udy=> M4DoflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[2NFY{Lz5{NUK2OlA3OzxxYU6=
SK-N-AS  M4\nRmZ2dmO2aX;uJGF{e2G7 NVi3ZmRrOTBizszNxsA> NITWOWE{OCCvaX6= NEXPTFlqdmS3Y3XzJJBpd3OyaH;yfYxifGmxbjDv[kDPui2lYYTlcolvKCi|ZYK2O|UqNCCyLVfTT|PPuiBqc3XyPUkh[W6mIHPvcoNwdWm2YX70JIhq\2incjDs[ZZmdHNib3[gZYN1cX[nLDD1cpBpd3OyaH;yfYxifGWmLDFOtk1k[XSnbnnu NEjDWHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2OlA3Oyd-MkWyOlYxPjN:L3G+
SK-N-AS  NXfZOlI{TnWwY4Tpc44hSXO|YYm= MVixNEDPxE4EoB?= MWKyOEBp MoTHbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJIN6[2yrbjDENS=> MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4NkC2N{c,OjV{Nk[wOlM9N2F-
SK-N-AS  NVTON2ZyTnWwY4Tpc44hSXO|YYm= NIr2WIYyOCEQvF5CpC=> NYTiXFNVOjRiaB?= MoHvbY5kemWjc3XzJJRp\SClQV3QJIxmfmWuc9Mg MofBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{Nk[wOlMoRjJ3Mk[2NFY{RC:jPh?=
SK-N-AS  NInGN3hE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NX7TVpJoOTBizszNxsA> MYWyOE81QCCq M{PIcoVvcGGwY3XzJJRqdWVvZHXw[Y5l\W62bImgZ4VtdHWuYYKgeoli[mmuaYT5xsA> NUXKcYFwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlYxPjNpPkK1NlY3ODZ|PD;hQi=>
granulosa cells Moj6SpVv[3Srb36gRZN{[Xl? NVrVcId7OTBizszN NX\EVIJ6OjRiaB?= NYXWflh1cW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gVmdUOiCycn;tc5RmeiCjY4Tpeol1gQ>? MlPlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|M{mxNFUoRjJ3M{O5NVA2RC:jPh?=
granulosa cells M1\HeWZ2dmO2aX;uJGF{e2G7 NEPGWZcyOCEQvF2= M1niN|I1KGh? Mnr2bY5kemWjc3XzJJRp\SCrboTlcpNqfHlib3[gSG5CN3C{b4TlbY4h[2:vcHzlfC=> MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN|OUGwOUc,OjV|M{mxNFU9N2F-
granulosa cells Mn\oSpVv[3Srb36gRZN{[Xl? NXvQT2tQOTBizszN NGqxemwyOi9{NDDo Mnm2bY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZicnXwc5J1\XJiYXP0bZZqfHliZn;yJJRp\SCub37n[ZN1KG[{YXft[Y51KCkkiKK4OVQwMzF6UlfTNk5NXUNr MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN|OUGwOUc,OjV|M{mxNFU9N2F-
granulosa cells NH;jSlZHfW6ldHnvckBCe3OjeR?= M3PsO|ExKM7:TR?= M{nJcVEzNzJ2IHi= M{nNV4lv[3KnYYPld{B1cGVibHX2[Yx{KG:owrDSS3MzyqCvUl7B M3\VXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{O5NVA2Lz5{NUOzPVExPTxxYU6=
BeWo  MUjGeY5kfGmxbjDBd5NigQ>? MYeyNOKhyrWP NXzWcFFIPDkEoHlCpC=> NHSyRVRFVVORwrC= NIfBUIFld3ewcnXneYxifGW|IITo[UBt\X[nbDDv[kBIS01vMR?= MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN4MkK2NEc,OjV|NkKyOlA9N2F-
BeWo  MYHGeY5kfGmxbjDBd5NigQ>? NVjZOVc{OjEEoNM1US=> Ml\QOFjDqGkEoB?= M1jrXWROW00EoB?= MXrkc5dvemWpdXzheIV{KHSqZTDs[ZZmdCCxZjDUUWVOTjF4 MlnoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|NkKyOlAoRjJ3M{[yNlYxRC:jPh?=
BeWo  NU\QSnVKTnWwY4Tpc44hSXO|YYm= NIL2TGQzOMLiwsXN MYm0POKhcMLi MoraSG1UV8Li NUfEU45CcW6lcnXhd4V{KHSqZTDi[ZRiNWiFRzDy[Yxm[XOn NYDteFNmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzOlIzPjBpPkK1N|YzOjZyPD;hQi=>
EM1  NVvrUZA3TnWwY4Tpc44hSXO|YYm= MWSxOgKBks7:TR?= MmHHOFghcA>? NYqz[214emWmdXPld{B1cGViZYjwdoV{e2mxbjDv[uKhVEmIwrDvduKhWFSJU{NCpIlvyqCFQVzSMUBwesLiRWDBR|Iue2muZX7j[YQhTU1zIHPlcIx{yqB? MkjHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|N{i2OlEoRjJ3M{e4OlYyRC:jPh?=
Primary bovine chondrocytes NU\sOmdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjKOe69VQ>? NWnIclZKPDhiaB?= MV3y[ZZmenOnczD0bIUhcW6qaXLpeI9zgSCnZn\lZ5Qhd2ZiY3Xs[YNwgGmkIH;uJJBzd2yrZnXyZZRqd25iaX6g[5Jwf3SqIIDsZZRmKGOqb37kdo9kgXSncx?= M1HudlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEC2NFE3Lz5{NUSwOlAyPjxxYU6=
RBMECs Mnz4SpVv[3Srb36gRZN{[Xl? M4G1NVXDqM7:TR?= M1HDeVEhcA>? NH;xNHljdG:la4OgeIhmKGGldHnuJIN6fG:|a3Xs[ZRwdiC{ZXHydoFv\2WvZX70JJNm\W5id3n0bEBGVUGSLVnJJJRz\WG2bXXueOKh M1S3S|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEG2OlUyLz5{NUSxOlY2OTxxYU6=
RBMECs MX3GeY5kfGmxbjDBd5NigQ>? NUnYSphkPcLizszN NIW4VlgyKGh? NV3MXndx[myxY3vzJJRp\SCHTVHQMWlKNWmwZIXj[YQh[2ijbnflJIlvKE2OQzDwbI9{eGixconsZZRqd25? Ml\HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MU[2OVEoRjJ3NEG2OlUyRC:jPh?=
RBMECs M1TremZ2dmO2aX;uJGF{e2G7 NGe2SFg2yqEQvF2= MWexJIg> M1O5NJJmfmW{c3XzJJRp\SClaHHu[4V{KGmwIGrPMVEh\Gm|dILpZpV1cW:wIIPl[Y4hf2m2aDDFUWFRNUmLIITy[YF1dWWwdB?= NV;ic25FRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVY3PTFpPkK1OFE3PjVzPD;hQi=>
RBMECs NXTqe4NPTnWwY4Tpc44hSXO|YYm= MmO3OeKh|ryP NFzGVW0yKGh? M2nyWIlvcGmkaYTzJJRp\SCmZXPy[YF{\WRib3[gZY1wfW62IH;mJHpQNTFiaX6gUWZ{KGmwZIXj[YQh[nliRV3BVE1KUQ>? MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzNk[1NUc,OjV2MU[2OVE9N2F-
RBMECs M1zOb2Z2dmO2aX;uJGF{e2G7 MVm1xsDPxE1? NUCxfIxzOSCq MV3wdoV3\W62czD0bIUhcW6lcnXhd4UhcW5iSGLQJIZtfXhiYXPyc5N{KHSqZTDCWGIhcW6mdXPl[EBjgSBiRV3BVE1KUQ>? MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzNk[1NUc,OjV2MU[2OVE9N2F-
RBMECs NG\4NlBHfW6ldHnvckBCe3OjeR?= M2DKeVXDqM7:TR?= MlzHNUBp M{[2cJBz\X[nboTzJJRp\SCHTVHQMWlKNWmwZIXj[YQhXEWHUjD2ZYx2\SCmZXPy[YF{\Q>? Mn\yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MU[2OVEoRjJ3NEG2OlUyRC:jPh?=
RBMECs NV;kPIhwTnWwY4Tpc44hSXO|YYm= MVe1xsDPxE1? M3joelEhcA>? NGPidlFjdG:la4OgeIhmKGGldHn2ZZRqd25ib3[gVohwSS:UT1PLJIlv\HWlZXSgZpkhTU2DUD3JTS=> NHvNN2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSxOlY2OSd-MkW0NVY3PTF:L3G+
RBMECs NHnKSGxHfW6ldHnvckBCe3OjeR?= MYqwMlA2NzBwNT:1JO69VQ>? Mo\XNE4zPSCq M1LhXolv[3KnYYPld{BkSU2SIHPvcoNmdnS{YYTpc44> NVnHXot3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVY3PTFpPkK1OFE3PjVzPD;hQi=>
ThGCs  NFrNfWtHfW6ldHnvckBCe3OjeR?= M175XFEx6oDMzszN MljVN{Bp M1jTSIlvcGmkaYTzJJRp\SCnZn\lZ5Qhd2ZiSELPNkBwdiCHRF6yJI1TVkF? NY\rbYhpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0N|MxOjdpPkK1OFM{ODJ5PD;hQi=>
ThGCs  M3Tp[GZ2dmO2aX;uJGF{e2G7 MXexNQKBks7:TR?= NHTsS3I16oDMaB?= NXvGZ3JzcW6lcnXhd4V{KEOxQ3yyMYlv\HWlZXSgSWRPOsLiZ3Xu[UBmgHC{ZYPzbY9v NWi1UYdWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0N|MxOjdpPkK1OFM{ODJ5PD;hQi=>
ThGCs  Mlz1SpVv[3Srb36gRZN{[Xl? NXLS[|ZQOTEkgJtOwG0> MmGyOQKBkmh? Mn7SZZVodWWwdIOgTGlHOUFibHX2[Yx{KHSqYYSge4Vz\SC|dHnteYxifGWmIHL5JGNwS2x{ Mny4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2M{OwNlcoRjJ3NEOzNFI4RC:jPh?=
LNCaP  NXK1WHhpTnWwY4Tpc44hSXO|YYm= NX\ZdZE1OTEEoN88US=> NE\KN5cyOiCqwrC= MlPzSG1UVw>? MX\pcoR2[2W|IHGg[JJidWG2aXOgbY5kemWjc3Wgc4YhS1KHQkGgZYN1cX[rdIm= NHvkbog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW0PFA6QSd-MkW1OFgxQTl:L3G+
BeWo M1nwPWZ2dmO2aX;uJGF{e2G7 MnXXNlDDqML3TR?= M4XMSFQ5yqCq MVnEUXNQ NGO0TGpqdmO{ZXHz[ZMhfGinIHHkbIV{cW:wIH;mJHRJWC1zIH3vco9kgXSncx?= NFrsXog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW2Olc1OCd-MkW1OlY4PDB:L3G+
BeWo NFzldotHfW6ldHnvckBCe3OjeR?= M{HnOlIxyqEEtV2= MUO0POKhcA>? M17TZmROW09? NHX2U4xqdmO{ZXHz[ZMhfGinIHTp[oZmemWwdHnheIlwdiCxZjDC[XdwKGOnbHzz NILqbm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW2Olc1OCd-MkW1OlY4PDB:L3G+
OCI-Ly18  Ml\jSpVv[3Srb36gRZN{[Xl? NWjCfGxrPDEEoN88US=> NV33d4FoOcLiaNMg M1XFXWROW09? NGHJOItqdmS3Y3XzJJRp\SCrbnPy[Y1mdnRib3[gZ2FOWCClb37j[Y51emG2aX;udy=> M2fCSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUe2NlIxLz5{NUW3OlIzODxxYU6=
OCI-Ly1  MmTWSpVv[3Srb36gRZN{[Xl? MnrjOFDDqM7:TR?= NFLoe3kyyqCqwrC= MVfEUXNQ M1PMW4lv\HWlZYOgeIhmKGmwY4LlcYVvfCCxZjDjRW1RKGOxbnPlcpRz[XSrb37z NIHpWJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW3OlIzOCd-MkW1O|YzOjB:L3G+
3T3-L1 NH\BTY9HfW6ldHnvckBCe3OjeR?= MnzTNk42NzVizszN MXSyOEBpyqB? Mljjd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNiQWTHUEBxem:2ZXnuJIV5eHKnc4Ppc44h[XRiYXzsJIRwe2W|IITld5Rm\A>? MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV7MEW5O{c,OjV3OUC1PVc9N2F-
HEK293  NVPOR49mTnWwY4Tpc44hSXO|YYm= NIjaO4Q26oDLwsXN NUXyTGFSOzBibXnu M3HrO4lv[3KnYYPld{BkSU2SIHzleoVtew>? NHvqcY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW5NVkxQCd-MkW1PVE6ODh:L3G+
hADSCs NULKTW41TnWwY4Tpc44hSXO|YYm= M4m0XVXjiIoEtV2= Ml7HN|AhdWmw M1TjRolv[3KnYYPld{BkSU2SIHzleoVtew>? Mlf0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3OUG5NFgoRjJ3NUmxPVA5RC:jPh?=
SH-SY5Y  NH:5dHBHfW6ldHnvckBCe3OjeR?= MkixNVDDqM7:TR?= M4S1elHDqGkEoB?= MkD0bY5kemWjc3XzJGFISzFibWLORUBt\X[nbB?= M2XvUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUm3OFM{Lz5{NUW5O|Q{OzxxYU6=
SH-SY5Y  NGLa[JJHfW6ldHnvckBCe3OjeR?= Mon1NVDDqM7:TR?= NV\WUVBtOcLiaNMg MnOwbY5kemWjc3XzJGxWSyCjY4Tpeol1gQ>? MmT2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3OUe0N|MoRjJ3NUm3OFM{RC:jPh?=
UACC-647  M3izO2Z2dmO2aX;uJGF{e2G7 M4fERVExyqEQvF2= NVfKOo52OTVibXnu NG\Zc|dFVVOR NVjVb4xUcW6lcnXhd4V{KGWHRkKgdIhwe3Cqb4L5cIF1cW:wIHzleoVte8Li MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdyM{CyOUc,OjV5MEOwNlU9N2F-
UACC-647  NYfZSpdjTnWwY4Tpc44hSXO|YYm= NXm0WZdUOTEEoN88US=> NXS5UYZLOTVibXnu M3TUSmROW09? NFTsN21qdmirYnn0d{BGWkticHjvd5Bpd3K7bHH0bY9v NH3ZWmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUewN|AzPSd-MkW3NFMxOjV:L3G+
UACC-647  NFPpWo1HfW6ldHnvckBCe3OjeR?= MWTEUXNQ NH\qSZRt\WGmczD0c{BiKHKrc3WgbY4h[0GPUDDs[ZZmdHNiKFXDOVDDqD4EoEKwMlM6yqEQvF2p NUXJSoQxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NFMxOjVpPkK1O|A{ODJ3PD;hQi=>
SC NWW3UYlOTnWwY4Tpc44hSXO|YYm= M4rr[FAvPSEQvF2= MX63NkBp Mm\TbY5kemWjc3XzJIJwfGhiS4LvfE0zOCCjbnSgU|Eh\XiycnXzd4lwdiCrbjDhfI9vNXKnbHH0[YQhW0O|IHL1eEBwdmy7IFvyc5guOjEEoB?= MknGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MEW4O|QoRjJ3N{C1PFc1RC:jPh?=
SC NWfQV|BiTnWwY4Tpc44hSXO|YYm= MUewMlUh|ryP NH;lUmszPCCq NFLRV3NucW2rY3vzJJRp\SCnZn\lZ5Qhd2ZiY1HNVEBidmGub3fzJI9vKE9zIHHu[EBOSlBiZYjwdoV{e2mxbh?= MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdyNUi3OEc,OjV5MEW4O|Q9N2F-
oocytes MVnGeY5kfGmxbjDBd5NigQ>? MojWOUDPxE1? MV6yOEBp MkXCZZR1\W63YYTld{BzcC2rboP1cIlvKGGldHnvckBwdiCxb3P5eIUhT1[ERDDzbYdvcW[rY3HueIx6yqB? MlHaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MEe4OVQoRjJ3N{C3PFU1RC:jPh?=
BeWo MVXGeY5kfGmxbjDBd5NigQ>? NYDYfVBYOTEkgJtOwG3DqA>? NYPrb4RwPzJiaB?= M{LweWROW09? NH35WZhu\WSrYYTld{BD\VexIHPlcIwh\GmoZnXy[Y51cWG2aX;u MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdzM{SyOUc,OjV5MUO0NlU9N2F-
GH3 Ml7SSpVv[3Srb36gRZN{[Xl? M33jS|HDqM7:TR?= MofNOk1p M{[zOYlv\HWlZYOgVHJNKGGwZDDCcYFtOSxiYoX0JI5wfCCFbH;jb{whdVKQQTDlfJBz\XO|aX;u MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{N{CxPEc,OjV5MkewNVg9N2F-
GH3 MVnGeY5kfGmxbjDBd5NigQ>? M1ztOVHDqM7:TR?= MWG2MYg> NFP6S2ZifHSnboXheIV{KHSqZTDjc5Jz\WyjdHnvckBj\XS5ZXXuJHBTVCCjbnSgRo1idDFiZYjwdoV{e2mxbh?= MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd{N{CxPEc,OjV5MkewNVg9N2F-
PC12 NVrCfIF{TnWwY4Tpc44hSXO|YYm= MkGwNlXDqM7:TR?= NX[yXnA{PDhiaB?= NI\yUXNi[3SrdnH0[ZMh[0GPUB?= MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4OUOwOUc,OjV5NkmzNFU9N2F-
BAECs MVvGeY5kfGmxbjDBd5NigQ>? NFq0S|czPSEQvF2= M4O1R|I1KGh? NE\ifIRmdmijbnPld{B1cGViYXP0bZZifGmxbjDv[kBRWEGUzsGgZpkhPSEQvF2gdoV{fmW{YYTyc4wtKFR2SGOsJI9zKDRvUFHQ MmnYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OUi4NlYoRjJ3N{m4PFI3RC:jPh?=
GLUTag  M3TzVmZ2dmO2aX;uJGF{e2G7 MlL4NVDjiIoEtV2= NH;OT|g1KGh? NEjDV2dqdmO{ZXHz[ZMhfGinIIDDVmVDKGyndnXsd{B4cXSqIITo[UBKSk2[ M{LHdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEOyOlMyLz5{NUizNlY{OTxxYU6=
GLUTag  M3nzOGZ2dmO2aX;uJGF{e2G7 NVrmO5M5OTEkgJpCuW0> MWqwM|IwPCCq M1vJZpN1cW23bHH0[ZMhT0ySLUGgd4VkemW2aX;uJINwfHKnYYTl[EB4cXSqIFnCUXg> M2nTWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEOyOlMyLz5{NUizNlY{OTxxYU6=
PBMC M4DScWZ2dmO2aX;uJGF{e2G7 MY[1NOKh|ryP MWiyOOKhcMLi NXrPPWpocW6qaXLpeJMhfGinIHnuZ5Jm[XOnZDDz[YNz\XSrb36gc4YhXE6IIHnu[JVk\WRiYomgeIhmKESSRR?= MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh4NkC3PUc,OjV6Nk[wO|k9N2F-
H295R  NUi0fmk2TnWwY4Tpc44hSXO|YYm= MXWxNOKh|ryP MoXSOFjDqGh? NX\PWmxscW6lcnXhd4V{KHO2ZYLvbYQhdWW2YXLvcIl1\XNiaX6geIhmKGGwZILv[4VvNCCvaX7ldoFtdy1iYX7kJIdtfWOxY3;yeIlkd2mmIIDheIh4[Xm| MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh4OUW1Okc,OjV6Nkm1OVY9N2F-
3T3-L1 preadipocytes MUPGeY5kfGmxbjDBd5NigQ>? MVWxNEDPxE4EoB?= M2LlPVEzKGh? NHf0RVdqdmS3Y3XzJGNTTUJicHjvd5Bpd3K7bHH0bY9vKGGwZDDDM2VDWM7{IHX4dJJme3Orb36= MnHxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MkiwOVgoRjJ3OUK4NFU5RC:jPh?=
PCCL3 NEDsVZRHfW6ldHnvckBCe3OjeR?= MUexNEDDvU1? MUiyOEBp MWPlcohidmOnczDEeW95OiCycn;tc5RmeiC2cnHud4NzcXC2aX;uJIFkfGm4aYT5xsDjiIt? M{juS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[wPVU3Lz5{NUm2NFk2PjxxYU6=
SCG M4rzXmZ2dmO2aX;uJGF{e2G7 NXPYZm12OTByIN88UeKh MnnTSG1UVw>? MUny[YR2[2W|IITo[UBmgGOrdHHibYxqfHlib3[gV2NIKG6ndYLvcpM> M{[1TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[yNVMzLz5{NUm2NlE{OjxxYU6=
HEK-293 MV7GeY5kfGmxbjDBd5NigQ>? MlHGN|Uh|ryPwrC= MY\EUXNQ MWLpcoR2[2W|IHGgZ49ve3CrY4XveZMh6oDeaX7hZ5RqfmG2aX;u5qCeKG:oIITo[UBMfjJwMTDjeZJz\W62 MmrKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkKxN|IoRjJ3OU[yNVMzRC:jPh?=
SCG MVjGeY5kfGmxbjDBd5NigQ>? MVWyNEDPxE4EoB?= MorJSG1UVw>? M33nWpJmfmW{c3nicJkhe3WycILld5NmeyCLS2[ge4l1cCCjIFnDOVAhd2ZiMkSuOEDPxE1? Ml\ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkKxN|IoRjJ3OU[yNVMzRC:jPh?=
PC-3 NEnWNo1E\WyuIG\pZYJqdGm2eTDBd5NigQ>? Ml;3OFAhyrWP NX3uSHI4OjRxNEivO|IhcA>? Mlm0SG1UVw>? NEXwVpBl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgeIlu\SCmZYDlcoRmdnSueR?= NF3qZpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN|g{Pid-Mk[wNlM5OzZ:L3G+
PC-3 NW\VZVNYTnWwY4Tpc44hSXO|YYm= M1;rfVQxKML3TR?= M4PYXlIhcA>? MW\EUXNQ MnrjcIVi\HNidH:gVHAzSSCjY4TpeoF1cW:w MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{M{izOkc,OjZyMkO4N|Y9N2F-
SH-SY5Y NUTBdZJTTnWwY4Tpc44hSXO|YYm= M4Ltd|MxKM7:TR?= NXq2UJVbOzBibXnu MkPSSG1UVw>? NXjsS5Bne2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgeIhmKGGldHn2ZZRqd25ib3[gVGtC NWLwcnlORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlUyOzdpPkK2NFI2OTN5PD;hQi=>
EndoC-βH1 NYLHXIIzTnWwY4Tpc44hSXO|YYm= MlTyOeKh|ryP Mn6wNUBp MXjs[YFleyC2bzDhJJN1em:wZzDjRW1RKGmwY4LlZZNm M1frZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEK4OVYzLz5{NkCyPFU3OjxxYU6=
EndoC-βH1 NG\CbJdHfW6ldHnvckBCe3OjeR?= Mk\ROeKh|ryP NXf5XlRIOSCq MlnWdI91\W62aXH0[ZMh\2y3Y3;z[U1qdmS3Y3XkJIlve3WuaX6gd4VkemW2aX;uJIlvKHSqZTDwdoV{\W6lZTDv[kBodHWlb4Pl MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{OEW2Nkc,OjZyMki1OlI9N2F-
RBMECs NXnWXGM{TnWwY4Tpc44hSXO|YYm= Mn7jOeKh|ryP M4DWcFEhcA>? NXm4SG9wcW6qaXLpeJMhTU2DUD3JTU1qdmS3Y3XkJIlv[WO2aY\heIlwdiCxZjDSZZAyyqB? NEWwfVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC0OFY3Oyd-Mk[wOFQ3PjN:L3G+
AML-12  MW\GeY5kfGmxbjDBd5NigQ>? MWqyNEDPxE1? NYnyNXZsOyCq Ml6xbY5lfWOnczD0bIUh\GWyaH;zdIhwenmuYYTpc44hd2ZiQ2LUR|LDqA>? NFzXSJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC0PFk5PSd-Mk[wOFg6QDV:L3G+
AML-12  MmHnSpVv[3Srb36gRZN{[Xl? MojXNlAh|ryP MX6zJIg> MUn1dE1z\We3bHH0[ZPDqFCpY{HhMOKhWGWyY3usJIFv\MLiR{\wZ:KhdVKQQTDs[ZZmdHN? NHrIcJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC0PFk5PSd-Mk[wOFg6QDV:L3G+
AML-12  NYHoVGZrTnWwY4Tpc44hSXO|YYm= MUmyNEDPxE1? M4r3OlEuQCCq NEXKTnNqdmO{ZXHz[ZMh\2y3Y3;z[UBxem:mdXP0bY9v M1\JRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MES4PVg2Lz5{NkC0PFk5PTxxYU6=
AML-12  NEfNWGlHfW6ldHnvckBCe3OjeR?= M1KydFIxKM7:TR?= NXK4SYR2OyCq NWjoS3FkfXC{ZXf1cIF1\XNidHjlJJBpd3OyaH;yfYxifGmxbjDs[ZZmdHNiYYSgWIhzNTRzMTDhcoQhW2W{LUS5Ny=> MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB2OEm4OUc,OjZyNEi5PFU9N2F-
Caco-2  NXXVW25ZTnWwY4Tpc44hSXO|YYm= MlTrNE4yNzFxMUCg{txO NFjCfJAzPCCq MV7pcoNz\WG|ZYOgUXJROiCycn;0[YlvKGyndnXs NUTNeYNrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOFkyODJpPkK2NFQ6OTB{PD;hQi=>
Caco-2  NVXqVYw5TnWwY4Tpc44hSXO|YYm= NWDQ[3FxOC5zL{GvNVAh|ryP MUOyNOKhdWmw MlnubY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJIlvfHKjY3XscJVt[XJiY1HNVEBt\X[nbIO= NW[0SlA{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOFkyODJpPkK2NFQ6OTB{PD;hQi=>
bovine oocytes M3LMSmZ2dmO2aX;uJGF{e2G7 NX\vVpM5OTBywrFOwG0> MmTjNVLDqGh? MULpcohq[mm2czD0bIUh\W[oZXP0JI9nKE6SUFGgZY5lN2:{IF7QVGMhfG9ic4TpcZVt[XSnIILld5VueHSrb36gc4YhdWWrb4Ppdy=> MkXYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNUG2NVEoRjJ4MEWxOlEyRC:jPh?=
BeWo  MWPGeY5kfGmxbjDBd5NigQ>? M1i2dVI26oDLzszN Mo\LNlQwPDhxN{KgbC=> MoX5cIVi\HNidH:gZY4hcW6lcnXhd4UhcW5idHjlJIV5eHKnc4Ppc44hd2Zib4To[ZIh\nW|aX;uJI1iemuncoO= NEjzR5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC1N|U1QSd-Mk[wOVM2PDl:L3G+
Spinal cords  MnTFSpVv[3Srb36gRZN{[Xl? MWqxxsDPxE1? NX7afZdGOzBibXnu M3\jb5N1cW23bHH0[ZMh[0GPUDDs[ZZmdHN? NE\WdVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGyOlkzPid-Mk[xNlY6OjZ:L3G+
MDCK  NVLuSZVjTnWwY4Tpc44hSXO|YYm= MU[xNEDDvU1? MkDWNlQhcA>? NVj4ZYVJTE2VTx?= NIDNWIZqdmirYnn0d{B1cGViaX7jdoVie2WmIHX4dJJme3Orb36gc4YhTk5iY3H1d4VlKGK7IGTHSk3PujF? MnTVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{MEKzOVIoRjJ4MkCyN|UzRC:jPh?=
MDCK  MoroSpVv[3Srb36gRZN{[Xl? M3LzNFExKML3TR?= NFnXcoIzPCCq MVXEUXNQ MVr1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBVT0ZvzsKxJIFv\CCFVFfGxsA> MlG0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{MEKzOVIoRjJ4MkCyN|UzRC:jPh?=
RPMI 8226 NVLkZVFQS2WubDDWbYFjcWyrdImgRZN{[Xl? M2j4SFAuOTByIN88US=> NH\Hcnc4OuLCiXi= MYfpcoR2[2W|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?= MonVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|ME[2NlQoRjJ4M{C2OlI1RC:jPh?=
H929 M1j5NWNmdGxiVnnhZoltcXS7IFHzd4F6 MlnWNE0yODBizszN MVK3NwKBkWh? M2TxPIlv\HWlZYOgZ4VtdCCmZXH0bEBld3OnIHTldIVv\GWwdHz5 Mn[4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|ME[2NlQoRjJ4M{C2OlI1RC:jPh?=
U266 NXPjW4hzS2WubDDWbYFjcWyrdImgRZN{[Xl? MX2wMVExOCEQvF2= M1LrUVcz6oDLaB?= M1HZOYlv\HWlZYOgZ4VtdCCmZXH0bEBld3OnIHTldIVv\GWwdHz5 MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjNyNk[yOEc,OjZ|ME[2NlQ9N2F-
OPM-2 M{PaTmNmdGxiVnnhZoltcXS7IFHzd4F6 MlrBNE0yODBizszN NUOzWWptPzMkgJno Ml\kbY5lfWOnczDj[YxtKGSnYYToJIRwe2ViZHXw[Y5l\W62bIm= MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjNyNk[yOEc,OjZ|ME[2NlQ9N2F-
INA-6 MoXtR4VtdCCYaXHibYxqfHliQYPzZZk> MYewMVExOCEQvF2= MXe3NwKBkWh? MnzxbY5lfWOnczDj[YxtKGSnYYToJIRwe2ViZHXw[Y5l\W62bIm= NETEelY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkOwOlYzPCd-Mk[zNFY3OjR:L3G+
RBMECs  NXXkOJlnTnWwY4Tpc44hSXO|YYm= M3eySlXDqM7:TR?= NULRb3VPOcLiaB?= NVjSbpFR[myxY3vzJJRp\SCUYXOxJIlv[WO2aY\heIlwdiCrbnT1Z4VlKGK7IFXNRXAuUUl? NYnvb|JQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOVgxOzlpPkK2N|U5ODN7PD;hQi=>
Mo-DCs NVTjc5NCTnWwY4Tpc44hSXO|YYm= Mlu4OVAh|ryP M1XDdFI16oDLaB?= MlfkdJJwdW:2ZYOgTWwuOjNicILv[JVkfGmxbjDpckB1cGVic4Xw[ZJv[XSjboSgc4Yhgnmvb4PhckB{fGmvdXzheIVlKE2xLVTDd:Kh Mli0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2MUK5OFgoRjJ4NEGyPVQ5RC:jPh?=
HEK293 MlTPSpVv[3Srb36gRZN{[Xl? M4rCclExKM7:TR?= MY[2JIg> NIK2coZqdmO{ZXHz[ZMheGixc4Doc5J6dGG2aX;uJI9nKG:4ZYLlfJBz\XO|ZXSgT2xJVDNiYYSgV|Q{Ow>? NHmzUGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkSzOVQ6QCd-Mk[0N|U1QTh:L3G+
ASK NEDvU2hHfW6ldHnvckBie3OjeR?= MXyxJIhz MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR7NkSxK|4zQDR7NkSxQE9iRg>?
Vero E6 M4r4[mFvfGm4aYLhcEBie3OjeR?= MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ4M{WzPUc,OTd4NkO1N|k9N2F-
epithelial cells MofaSpVv[3Srb36gZZN{[Xl? NFzoNpoyKHWP MmXLOEwhPixiYX7kJFgh\GG7cx?= NHvqUlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUm2Olc5QSd-MUm5OlY4QDl:L3G+
HepG2 (DPX-2) MWTGeY5kfGmxbjDhd5NigQ>? MkPZNlQhcHK| Ml3TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB7Nk[wOFMoRjJyOU[2NFQ{RC:jPh?=
HepG2 NGP5eo1HfW6ldHnvckBie3OjeR?= MmDhNlQhcHK| M1LJ[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOU[2NFQ{Lz5{MEm2OlA1OzxxYU6=
HepG2 (DPX-2) M1m3OGZ2dmO2aX;uJIF{e2G7 NUTafowyOjRiaILz MnvIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB7Nk[wOFMoRjJyOU[2NFQ{RC:jPh?=
HEK293T MV3GeY5kfGmxbjDhd5NigQ>? NWTPRY9VOTBidV2= M1zqOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{i3N|I2Lz5{NEO4O|MzPTxxYU6=
HEK293 MnLlSpVv[3Srb36gZZN{[Xl? NHHhXmIyOCC3TR?= M{DwWVE3KGi{cx?= M1m0VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEO1OVEzLz5{NkSzOVUyOjxxYU6=
MCF7 MofWR5l1d3SxeHnjbZR6KGG|c3H5 NIT1cno1QCCqcoO= MnS2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6M{i2PVIoRjJ6OEO4OlkzRC:jPh?=
HEK293 MUTGeY5kfGmxbjDhd5NigQ>? M4fXWlMxKG2rboO= NW\3[ng5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNFYyPzZpPkOwNFA3OTd4PD;hQi=>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
cleaved caspase-3 / caspase-3; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-3

cleaved caspase-9 / caspase-9 ; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-9.

β-catenin; 

PubMed: 30863177     


(A, B) The protein expression of cytoplasmic and nuclear β-catenin in Toledo and NK-92 cells in the presence of 0, 10, 20, or 40 μM forskolin was detected by Western blotting.

c-myc / Cyclin D1; 

PubMed: 30863177     


(C, D) Western blotting analysis of the total protein expression of c-myc and cyclin D1 influenced by 0, 10, 20, or 40 μM of forskolin in Toledo and NK-92 cells (n=3, *P<0.05, forskolin group vs control group).

pS6K1 / S6K1 / pCREB / CREB; 

PubMed: 31112131     


Forskolin inhibits mTORC1 in multiple cell lines. PC3, LNcap/AR, H1299, H1944, MDA-MB-231, MEF, HAP1, COS7, HeLa, MIA Paca-2, and PANC-1 were treated with or without 10 μM forskolin for 1 h and mTORC1 activity, CREB phosphorylation, and loading controls were analyzed.

p-JNK / JNK / P-p38 / p38; 

PubMed: 20070884     


L929 cells were pretreated with forskolin (10 μM) for various times as indicated, followed by stimulation with or without 10 ng/ml TNF-α for 15 min.

30863177 31112131 20070884
Immunofluorescence
5hmC; 

PubMed: 29239726     


Schwann cells were treated with forskolin (10 μM) for 3 hr followed by washout. 5hmC induction was detected at of 0, 3, and 24 hr time points following treatment. Cells continuously treated with forskolin (5, 10 μM) for 24 hr showed comparable 5hmC levels. Scale bar = 20 μm. 

Fe(II); 

PubMed: 29239726     


AMP (100 mM) treatment for 4 hr did not induce labile Fe(II) while AC activators (forskolin (100 mM), bicarbonate (50 mM)) and PDE inhibitors (caffeine (100 mM), IBMX (100 mM)) increased labile Fe(II) detected by Trx-Puro probes.

CYP17A1 / CYP21A2; 

PubMed: 25334044     


H295R cells were treated with 8-Br-cAMP or forskolin for 48 h under growth conditions, and fixed with 4% paraformaldehyde. (A) Immunostaining for CYP17A1. Red staining shows the anti-CYP17A1 antibody and blue staining shows DAPI (cell nuclei). (B) Immunostaining for CYP21A2. Red staining shows the anti-CYP21A2 antibody and blue staining shows DAPI (cell nuclei). Scale bars represent 100 µm.

29239726 25334044
Growth inhibition assay
Cell viability; 

PubMed: 30863177     


(C) MTT assay was conducted to test the cell growth after Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (D) Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50 of forskolin. (F) MTT assay was conducted to test the cell growth after NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (G) NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50of forskolin. 

30863177

お薦めの試験操作(参考用のみ)

溶解度 (25°C)

体外 DMSO 82 mg/mL (199.75 mM)
Water Insoluble
Ethanol '37 mg/mL '37

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 410.5
化学式

C22H34O7

CAS No. 66575-29-9
Storage powder
in solvent
別名 Coleonol, Colforsin
Smiles CC(=O)OC1C(C2C(CCC(C2(C3(C1(OC(CC3=O)(C)C=C)C)O)C)O)(C)C)O

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

cAMPシグナル伝達経路

Tags: Colforsin (Forskolin)を買う | Colforsin (Forskolin) ic50 | Colforsin (Forskolin)供給者 | Colforsin (Forskolin)を購入する | Colforsin (Forskolin)費用 | Colforsin (Forskolin)生産者 | オーダーColforsin (Forskolin) | Colforsin (Forskolin)化学構造 | Colforsin (Forskolin)分子量 | Colforsin (Forskolin)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID